Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Canc... (ls when provided after transurethral res...)

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy

Date:8/19/2007

ls, when provided after transurethral resection, VALSTAR patients had a median 21 months to documented recurrence of disease.

VALSTAR has been shown to induce complete response in only about 1 in 5 patients with BCG-refractory CIS. It is important to note that delaying cystectomy could lead to development of metastatic bladder cancer.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) XR and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty and DELATESTRYL(R) to treat male hypogonadism. Indevus currently markets its products through an approximately 100-person specialty sales force. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA(R) XR, NEBIDO(R), VANTAS(R) and SUPPRELIN(R) LA; the early state of products under development; uncert
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting
2. Indevus Reports Positive Data From Phase III NEBIDO Trial
3. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
4. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
5. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
6. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
7. Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter
8. First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder
9. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
10. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
11. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs

Post Your Comments:

Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Canc...(ls when provided after transurethral res...),Health